SCHEMBL408223

SCHEMBL408223

N/C(=N\O)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL284532 1.00
SCHEMBL284533 1.00
Hydrochloric Acid SCHEMBL11798083 0.97
SCHEMBL642579 0.88
SCHEMBL4424571 0.88
SCHEMBL4741407 0.88
SCHEMBL642580 0.88
SCHEMBL14400257 0.85 LMNA (0.45)
SCHEMBL15599086 0.85 LMNA (0.45)
SCHEMBL21255728 0.85 LMNA (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111620348-B Preparation method of sodium silicate for nano silicon dioxide 安徽龙泉硅材料有限公司 2022-11-22 CN claimed
CN-111620348-A Preparation method of sodium silicate for nano silicon dioxide 安徽龙泉硅材料有限公司 2020-09-04 CN claimed
US-20260132147-A1 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIV (US) 2026-05-14 US disclosed
US-12479857-B2 Bax inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2025-11-25 US disclosed
US-12319676-B2 Substituted amide compounds useful as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2025-06-03 US disclosed
US-12227496-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2025-02-18 US disclosed
CN-119301113-A Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors 豪夫迈·罗氏有限公司 2025-01-10 CN disclosed
US-20240374612-A1 IMIDAZOBENZODIAZEPINES FOR TREATMENT OF COGNITIVE AND MOOD SYMPTOMS CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) 2024-11-14 US disclosed
CN-113677659-B Substituted amide compounds useful as farnesoid X receptor modulators 百时美施贵宝公司 2024-09-06 CN disclosed
EP-4399211-A1 IMIDAZOBENZODIAZEPINES FOR TREATMENT OF COGNITIVE AND MOOD SYMPTOMS UWM Research Foundation, Inc. (US) 2024-07-17 EP disclosed
US-12030835-B2 Substituted amide compounds useful as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-09 US disclosed
WO-2007115930-A1 THIAZOLYLDIHYDROINDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
WO-2007115931-A1 THIAZOLYLDIHYDROCYCLOPENTAPYRAZOLES FOR USE AS PI3-KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070238746-A1 THIAZOLYL-DIHYDRO-CHINAZOLINE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070238730-A1 THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070238730-A1 THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070197522-A1 Dpp-iv inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-08-23 US disclosed
US-20070197522-A1 Dpp-iv inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-08-23 US disclosed
WO-2005095343-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-10-13 WO disclosed